read more: "Avigen, Inc., (AVGN) announced that it has agreed to sell its AAV gene therapy assets to Genzyme Corp. Under the terms of the agreement, Genzyme will acquire all of Avigen's non-pain related AAV assets. The assets include all rights to an extensive patent estate and Avigen's Parkinson's disease clinical trial program, which is in a phase I /II study currently underway at University of California, San Francisco (UCSF)."